Amgen’s blood cancer drug is working wonders

August 5, 2014 3:30 AM

11 0

Amgen’s blood cancer drug is working wonders

Amgen Inc, the world’s largest pharmaceutical company, announced on Monday that its new drug Kyprolis delays the worsening of multiple myeloma when combined with standard therapy compared with standard therapy alone. Amgen acquired Kyprolis after its purchase of Onyx Pharmaceuticals for $10 billion last year. Sales of the drug have already accounted for $146 million in the first half of this year.

Researchers conducting a study called Aspire are following 792 patients with relapsed multiple myeloma who received prior treatment. On standard treatment consisting of Celgene’s existing drug Revlimid combined with dexamethasone, patients averaged 17.6 months of progression-free survival. Patients ...

Also read: Hillary Clinton's Popular Vote Lead Over Donald Trump Now Exceeds 2.3 Million

Read more

To category page

Loading...